Clinical Trial Update: Diagnostic Accuracy of the "LLIFT", a Novel Non-invasive Biomarker for the Diagnosis of Non Alcoholic Fatty Liver (NAFL) and SteatoHepatitis (NASH) in a Population With High Risk of Metabolic Syndrome"

View source ↗

Summary

This completed trial assesses the diagnostic accuracy of LLIFT, a novel non-invasive biomarker, for diagnosing non-alcoholic fatty liver disease and non-alcohol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Non-alcoholic Steatohepatitis

Snippet

Sponsor: University Hospital, Lille | Conditions: Obesity, NASH - Nonalcoholic Steatohepatitis | Status: COMPLETED